Agios Pharmaceuticals(AGIO) ZACKS·2025-02-14 14:26Core Viewpoint - Agios Pharmaceuticals reported a wider loss per share in Q4 2024 compared to estimates, despite a significant increase in revenues driven by its marketed drug Pyrukynd, which is also undergoing further development for additional indications [1][2][3]. Financial Performance - The company incurred a loss of $1.74 per share in Q4 2024, compared to a loss of $1.72 per share in the same quarter last year [1]. - Revenues for Q4 2024 were $10.7 million, slightly exceeding the consensus estimate of $10 million, and representing a 51% increase from $7.1 million in the year-ago quarter [2]. - For the full year 2024, Agios generated revenues of $36.5 million, reflecting a 36.1% year-over-year increase [6]. Product Performance - All revenues in Q4 2024 were generated from Pyrukynd, which is approved for treating hemolytic anemia in adults with pyruvate kinase deficiency [3]. - Pyrukynd revenues increased by 20% sequentially, with 130 patients currently on therapy, marking a 2.4% increase from Q3 2024 [4]. Expenses - Research and development expenses rose by 6.8% year-over-year to $82.8 million, attributed to higher workforce-related costs [4]. - Selling, general, and administrative expenses surged by 46.5% year-over-year to $51.7 million, driven by preparations for a potential launch of Pyrukynd for thalassemia [5]. Pipeline Developments - Agios is developing Pyrukynd for additional indications, including sickle cell disease and thalassemia, with a supplemental new drug application accepted by the FDA for thalassemia [8][9]. - The company completed enrollment in a phase III study for Pyrukynd in sickle cell disease, with top-line data expected in late 2025 [10]. - Agios is also conducting studies on a novel PK activator, tebapivat, for myelodysplastic syndromes and sickle cell disease [12]. Market Performance - Over the past year, Agios shares have increased by 24.2%, contrasting with a 3.6% decline in the industry [2].